IOBT IO Biotech
- 1.000
- -0.500-33.33%
- 1.010
- +0.010+1.00%
IO Biotech News
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4
IO Biotech Analyst Ratings
H.C. Wainwright Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Cuts Target Price to $4
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $7
IO Biotech Analyst Ratings
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Announces Target Price $7
Buy Rating on IO Biotech: Promising Clinical Outcomes and Strategic Positioning for Regulatory Success
Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)
H.C. Wainwright Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $12
TD Cowen Maintains IO Biotech(IOBT.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on IO Biotech (IOBT)
HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating
IO Biotech Analyst Ratings
Optimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data Timeline
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
IO Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)
Promising Clinical Trials and Favorable Safety Profile Drives Buy Rating for IO Biotech
IO Biotech (IOBT) Receives a Buy From TD Cowen
Analysis
Price Target
No Data
